Addex Therapeutics GAAP EPS of -CHF0.02, revenue of CHF0.06M

Like
Comment
Favorite

Addex Therapeutics GAAP EPS of -CHF0.02, revenue of CHF0.06M

seekingalpha2024-11-22

Addex Therapeutics press release (NASDAQ:ADXN): Q3 GAAP EPS of -CHF0.02.
Income of CHF0.06M (-81.8% Y/Y).
Completed Q3, 2024 with cash and cash equivalents of CHF3.3 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

07:27
Larsen and Toubro - L&T Energy Green Tech and John Cockerill Energy Collaborate
07:26
Trainline Plc - Holding(S) in Company
07:24
S4 Capital Plc : Jefferies Raises Target Price to 55P From 50P
07:22
Mila Resources : Signed Drilling Contract to Commence Drilling at Yarrol Gold Project in April
07:22
Ibj Inc - Total Voting Rights After Acquisition to Be 9.80%

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2485565239?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-11-22 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485565239","market":"sh","top_or_hot":-1,"title":"Addex Therapeutics GAAP EPS of -CHF0.02, revenue of CHF0.06M","media":"seekingalpha","content":"<html><body><ul>\n<li>Addex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> press release  (<span>NASDAQ:ADXN</span>): Q3  GAAP EPS of -CHF0.02.</li>\n<li>Income of CHF0.06M (-81.8% Y/Y).</li>\n<li>Completed Q3, 2024 with cash and cash equivalents of CHF3.3 million.</li>\n</ul></body></html>","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Addex Therapeutics GAAP EPS of -CHF0.02, revenue of CHF0.06M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAddex Therapeutics GAAP EPS of -CHF0.02, revenue of CHF0.06M\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-22 17:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4320135-addex-therapeutics-gaap-eps-of--chf002-revenue-of-chf006m><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Addex Therapeutics press release  (NASDAQ:ADXN): Q3  GAAP EPS of -CHF0.02.\nIncome of CHF0.06M (-81.8% Y/Y).\nCompleted Q3, 2024 with cash and cash equivalents of CHF3.3 million.</p>\n\n<a href=\"https://seekingalpha.com/news/4320135-addex-therapeutics-gaap-eps-of--chf002-revenue-of-chf006m\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADXN","symbol_name":"Addex Therapeutics Ltd","start_time":0,"source_url":"https://seekingalpha.com/news/4320135-addex-therapeutics-gaap-eps-of--chf002-revenue-of-chf006m","article_id":"2485565239","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485565239","pubTimestamp":1732266375,"columns":[],"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"Addex Therapeutics press release  (NASDAQ:ADXN): Q3  GAAP EPS of -CHF0.02.\nIncome of CHF0.06M (-81.8% Y/Y).\nCompleted Q3, 2024 with cash and cash equivalents of CHF3.3 million.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ADXN":"Addex Therapeutics Ltd","LENZ":"Therapeutics"},"translate_title":"Addex Therapeutics GAAP每股收益为-0.02瑞士法郎，收入为0.06万瑞士法郎","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADXN":0.9,"LENZ":1},"content_text":"Addex Therapeutics press release  (NASDAQ:ADXN): Q3  GAAP EPS of -CHF0.02.\nIncome of CHF0.06M (-81.8% Y/Y).\nCompleted Q3, 2024 with cash and cash equivalents of CHF3.3 million.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}